NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorRiesco Martinez, M. C.
dc.contributor.authorCapdevila, J.
dc.contributor.authorAlonso, V.
dc.contributor.authorTeule, A.
dc.contributor.authorGrande, E.
dc.contributor.authorJimenez-Fonseca, P.
dc.contributor.authorBenavent, M.
dc.contributor.authorAlonso Gordoa, T.
dc.contributor.authorCustodio, A.
dc.contributor.authorHierro Carbo, C.
dc.contributor.authorLopez, C.
dc.contributor.authorSevilla Garcia, I.
dc.contributor.authorGarcia-Carbonero, R.
dc.contributor.authoraffiliation[Riesco Martinez, M. C.] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Garcia-Carbonero, R.] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Capdevila, J.] Vall Hebron Inst Oncol VHIO, Vall Hebron Univ Hosp, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Alonso, V.] Hosp Univ Miguel Servet, Inst Aragones Invest Sanitaria, Zaragoza, Spain
dc.contributor.authoraffiliation[Teule, A.] Inst Catala Oncol ICO, Med Oncol Dept, Lhospitalet De Llobregat, Spain
dc.contributor.authoraffiliation[Grande, E.] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Jimenez-Fonseca, P.] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain
dc.contributor.authoraffiliation[Benavent, M.] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Alonso Gordoa, T.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Custodio, A.] Hosp Univ La Paz, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Hierro Carbo, C.] ICO Badalona, Med Oncol, Badalona, Spain
dc.contributor.authoraffiliation[Lopez, C.] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain
dc.contributor.authoraffiliation[Sevilla Garcia, I.] Hosp Clin Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
dc.contributor.funderBristol-Myers Squibb
dc.date.accessioned2025-01-07T15:15:24Z
dc.date.available2025-01-07T15:15:24Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.2092
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420420897/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26986
dc.identifier.wosID573469101475
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS783-S783
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleNICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía